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Abstract
Background: The value of oocyte cryopreservation in older women remains controversial. The aim of this study
was to report the oocyte freezing experience in women aged 40 and older at a single fertility center.
Findings: One hundred fifty eight women (mean age 43.9 ± 0.2) who underwent minimal ovarian stimulation IVF
were enrolled. IVF protocol included the use of clomiphene citrate (50 mg/day) or letrozole (2.5 mg/day) with or
without low dose gonadotropins (started at 75 IU/day and increased as needed to 150 IU/day). 584 retrieved oocytes
(2.1 ± 0.15 per patient) yielded 532 mature MII oocytes that were frozen. After thawing and fertilization by ICSI, a total
of 344 embryos (1.9 ± 0.1 per patient) were formed. A total of 57 relatively good embryos were transferred and yielded
three live births (5.3 % per embryo transfer), three spontaneous abortions, and one chemical pregnancy.
Conclusions: These data are important in counseling older women who desire autologous oocyte freezing.
Keywords: IVF, Oocyte cryopreservation, Minimal ovarian stimulation, Mild ovarian stimulation, Oocyte freezing
Introduction
Oocyte cryopreservation has wide clinical implications
especially for women who have no partner or stand to
lose ovarian function due to aging [1]. Following embryo
cryopreservation, oocyte cryopreservation is the second
most commonly used method of fertility preservation for
medical indications [1]. In January 2013, the American
Society for Reproductive Medicine declared that the
technique of oocyte cryopreservation (egg freezing) is
no longer experimental [2]. In young women, there is
good evidence that fertilization and pregnancy rates
are similar to IVF/ICSI with fresh oocytes when vitri-
fied/warmed oocytes are used as part of IVF/ICSI. Al-
though data are limited, no increase in chromosomal
abnormalities, birth defects, and developmental deficits has
been reported in the offspring born from cryopreserved
oocytes when compared to pregnancies from conventional
IVF/ICSI and the general population.
Over the past decade, vitrification has been developed
as an alternative to slow-freeze [3, 4]. Most data in
women suggest that post-thaw survival rates of vitrified
oocytes are much higher than oocytes that underwent
slow-freeze [3, 4]. Vitrification protocols use high initial
concentrations of cryoprotectant and ultra-rapid cooling
to solidify the cell into a glass-like state in order to pre-
vent the formation of ice crystals. Vitrification is cur-
rently being applied to the cryopreservation of embryos,
oocytes, and ovarian tissue [2, 5]. Embryo cryopreserva-
tion and oocyte cryopreservation in young women are
well-established techniques among IVF centers [6].
However, data pertaining to autologous oocyte cryo-
preservation by vitrification in older women, especially
those older than 40, remain scarce.
Minimal and mild ovarian stimulation IVF usually
refers to the use of low-dose gonadotropins with or
without a sequential administration of clomiphene cit-
rate or letrozole [7]. Typically, minimal/mild ovarian
stimulation usually refers to gentle stimulation protocols
that yield a maximum of five to six oocytes [7]. It has been
suggested that the relatively small number of oocytes ob-
tained after gentle ovarian stimulation may represent the
best of the cohort in a given cycle [8]. However, data per-
taining to the outcome of autologous oocyte freezing, in
particular live birth, in older women using minimal/mild
ovarian stimulation IVF is understudied. Thus, the pur-
pose of this manuscript was to report the outcome of fro-
zen oocytes by vitrification in women aged 40 or older
who underwent minimal/mild stimulation IVF.* Correspondence: johnzhang98@gmail.com
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Materials and methods
This is a retrospective chart review study that involved
158 women aged 40 or older who underwent minimal/
mild ovarian stimulation IVF at a single fertility center
(New Hope Fertility Center, New York). Reasons for au-
tologous oocyte cryopreservation included: women who
had no male partner, women who desired to preserve
their future ability to have children because they wanted
to delay childbearing, women who had fear of losing all
oocytes due to aging, women with a family history of
early menopause fearing that their oocytes would be de-
pleted at an early age. All patients were counseled that
the efficacy and the success (i.e., achieving a live birth)
of autologous oocyte freezing is understudied in women
aged over 40. They were also informed that the probabil-
ity of getting pregnant with frozen oocyte could be low
after the age of 40 although specific percentages could
not be quoted. The studay was approved by the Institu-
tional Review Board of New York Downtown Hospital
(IRB approval reference number: JZ-09-08) [9].
After oral contraceptive pill pre-treatment for approxi-
mately 3 weeks and adequate suppression, minimal/mild
ovarian stimulation was started with an extended regimen
(from cycle day 3 until the day before triggering) of clomi-
phene citrate (50 mg/day orally) or letrozole (2.5 mg/day)
in conjunction with low dose of gonadotropin injections
(75 IU/day and increased as needed to 150 IU/day)
(Bravelle and/or Menopur, Ferring, Parsippany, NJ;
Follistim, Merck, White House Station, NJ; or Gonal F,
EMD Serono, Rockland, MA) starting on cycle day 4
to 7 depending on the response. Ovarian response was
monitored using serial transvaginal ultrasound and
serum blood measurement for estradiol, progesterone and
luteinizing hormone. No hypothalamic-pituitary ovulation
suppression using GnRH agonist or antagonist was used in
this protocol. The final maturation of oocytes was induced
by a nasal GnRH agonist (Synarel nasal spray 2 mg/mL,
Pfizer, New York, NY) when the lead follicle is >18 mm.
Retrieved oocytes were checked for maturity and mature
oocytes were cryopreserved by vitrification.
Oocytes were vitrified using the Kitazato commercial kit
(Dibimed Biomedical Supply S.L., Valencia, Spain) as previ-
ously descibed [10–12]. The oocytes were aspirated with a
minimal volume of HEPES culture media then placed in a
micro-droplet containing the Basic Solution. The oocytes
were allowed to acclimate to the new solution for approxi-
mately 10–30 s then placed in a drops of Equilibration
Solution containing 7.5 % (vol/vol) ethylene glycol
(EG) + 7.5 % dimethyl sulfoxide (DMSO) at room
temperature for 15 min. After 6 min, the oocytes were
transferred into a Vitrification Solution drop contain-
ing 15 % EG + 15 % DMSO + 0.5 M sucrose for a total
of 50 s before being loaded into a Cryotop (fine and
thin strip) that is quickly plunged into liquid nitrogen.
Oocyte thawing and fertilization by ICSI was per-
formed for all couple when using either the male partner
or donor sperm. While all semen parameters are import-
ant during an ICSI cycle, motility is the most important
because it is an indication of living sperm. For this study
all sperm injected into oocytes were motile. When choo-
sing motile sperm for injection, basic head, neck and tail
morphology were considered, and in all cases the best
sperm available were chosen over any dysmorphic sperm
in the samples. The embryos were cultured in a single
global total medium (LifeGlobal Group LLC) that contains
proteins, salts, amino acids, buffer (NaHCO3), glucose,
pyruvate, lactate and antibiotics (gentamicin). All embryos
were placed in incubators containing 5 % CO2 that results
in a physiologic pH of approximately 7.30.
A single embryo was transferred in a subsequent artifi-
cially prepared cycle with oral estradiol (Estrace, Actavis
Pharma, Inc, Parsippany, NJ) [13]. All patients started
oral estradiol at 4 mg/d orally for 10 days starting on the
third day of menstruation. The dose of Estrace was sub-
sequently increased to 6–8 mg/d in cases where serum
estradiol level was less than 200 pg/mL and/or when
ultrasound images showed an endometrial thickness of
less than 7 mm. Oral estradiol treatment was then contin-
ued for 7–14 days until the endometrial thickness was
more than 7 mm. Progesterone vaginal insert (prometrium)
200 mg three time daily was administered to support the
luteal phase and oral estradiol was continued along with
progesterone. Embryo transfer was performed on the 5th
day of progesterone supplementation for cleavage stage em-
bryos and on the 7th day of progesterone supplementation
for blastocyst embryos. All embryo transfers were per-
formed under in ultrasound guidance to ensure correct
placement, which is 1–2 cm from the uterine fundus.
Data were presented as mean ± standard error of the
mean. The main outcome was live birth per embryo
transfer. Pearson correlation was performed to evaluate
the association between age and clinical parameters such
as day 3 FSH, peak serum estradiol level, number of oocytes
retrieved, and number of mature metaphase II oocytes.
Pearson correlation was also performed to evaluate the
association between BMI and the number of oocytes re-
trieved and mature metaphase II oocytes. Statistical signifi-
cance was declared if the two-sided p-value was ≤ 0.05.
Statistical analyses were performed using statistical
software GraphPad Prism six (GraphPad Software, Inc.
La Jolla, CA, USA).
Results
The participants had a mean age of 43.9 ± 0.2 years (range:
40 to 49 years), mean body mass index of 23.6 ± 0.4 kg/m2
(range: 17 to 39 kg/m2) and a mean baseline day 3 FSH of
12.6 ± 0.6 mIU/mL (range: 2 to 48 mIU/mL). The mean
number of days of ovarian stimulation with gonadotropins
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injections was 6.1 ± 0.3 and the mean peak estradiol level
660.7 ± 37.4 pg/mL.
There was a positive correlation between age and
day 3 FSH (r = 0.2, p = 0.007). There was also a nega-
tive correlation between age and peak estradiol level
(r = −0.17, p = 0.005), the number of oocytes retrieved
(r = −0.2, p = 0.001), and the number of mature meta-
phase II oocytes (r = −0.19, p = 0.001) (Fig. 1). There
was no correlation between BMI and the number of
oocytes retrieved (r = −0.05, p = 0.6) or the number of
mature metaphase II oocytes (r = −0.05, p = 0.6).
A total of 584 oocytes (2.1 ± 0.15 per patient) were re-
trieved; 532 of which were mature metaphase II oocytes
that were cryopreserved by vitrification. Four patients
had no (i.e., zero) oocytes retrieved. After thawing and
fertilization of the 532 mature oocytes by ICSI, 485 em-
bryos (1.9 ± 0.1 per patient) were formed. Table 1 reports
the different stages of embryos formed and the number
of embryos formed in each category. A total of 57 rela-
tively good embryos were transferred and yielded six
clinical pregnancies (10.5 % clinical pregnancy rate per
transfer) and one chemical pregnancy. Of the clinical
pregnancies, three pregnancies yielded live births (5.3 % live
birth rate per transfer) and three spontaneous abortions.
Discussion
The number of women over 40 years of age seeking in-
fertility treatment has been steadily increasing in the
past decade due to postponing childbearing in career
women as well as the desire of pregnancy in couples
starting a second family [14]. The decision to delay child-
bearing has biologic consequences. While the onset and
progression of reproductive decline is unique for each indi-
vidual, it is inevitable once a woman reaches her 30’s years.
Women with diminished ovarian reserve have decreased
response to gonadotropins, require higher doses of gonad-
otropins, have higher miscarriage rates, and have lower
pregnancy/live-birth rates [15–18]. For those who desire to
delay childbearing and have good ovarian reserve, oocyte
freezing represents a good option [2]. However, while the
success of oocyte freezing may be as high as 45 % [19], it
declines rapidly once a woman reaches age 35 [15].
Several studies have evaluated the impact of age on
the outcome of oocyte cryopreservation [20] and dem-
onstrated that success rates with oocyte cryopreserva-
tion via either slow-freeze or vitrification decline with
maternal age [20–22]. A study (n = 450 patients) on
women who underwent oocyte thaw cycles using pre-
viously vitrified supernumerary oocytes found that mater-
nal age was inversely correlated with delivery rates [22].
Another study (n = 182 participants) reported that ongoing
pregnancy rate using oocyte vitrification/warming cycles
was negatively correlated with age [19]. In that study, a sig-
nificant difference in cumulative pregnancy rate was found
between age group < 34 years and age group 41–43 years
(p = 0.006).
Fig. 1 Correlations between age and day 3 FSH, peak estradiol levels, number of oocytes retrieved and number of mature metaphase II (MII)
oocytes. There was a positive correlation between age and day 3 FSH; however, there was a negative correlation between age and 1) peak
estradiol level, 2) the number of oocytes retrieved, and 3) the number of mature MII oocytes
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Several studies using slow-freeze protocols suggested
that success rates were lower with advanced maternal
age. In a large cohort study (n = 2046 patients), oocyte
survival was similar in women < or > than 38 years old
[20]. As expected, women aged > 38 had significantly lower
implantation rates (6.5 % vs. 10.9 %, p = 0.01) and preg-
nancy rates (10.1 vs. 18.7 %, p = 0.02) compared to women
aged < 38 [20]. Unlike our study, the mean patient age at re-
trieval was 35.04 ± 3.97 years (range, 21–45 years). Another
study (n = 342 patients) using a slow-freeze protocol re-
ported pregnancy rates of oocyte cryopreservation in three
groups of women by age: ≤34 years (group A, mean age
31.1 ± 2.50), 35–38 years (group B, mean age 36.4 ± 1.07),
and ≥ 39 years (group C, mean age 40.6 ± 1.36) [21]. In
groups A, B and C respectively, the implantation rates were
16.7, 11.6, and 10.8 %, the pregnancy rates per thaw cycle
were 24.3, 18.9, and 16.1 %, and the pregnancy rates per
embryo transfer were 27.7, 21.4, and 17.6 %. The outcomes
were comparable among the three groups although there
was a trend for all outcomes to be lower in older women
(p > 0.05 for all) [21].
With the efficiency of vitrification, autologous oocyte
banking appears to be a solution for later motherhood.
This report presents a description on the quality and
outcome of embryos following oocyte cryopreservation
in women aged 40 and older (age range: 40–52) who
underwent gentle ovarian stimulation IVF at a single fer-
tility center. It also reports the pregnancy rate per single
embryo transfer of those who thawed and fertilized their
oocytes. Although these data are useful in counseling
older women who desire autologous oocyte freezing, a
lingering question for patients and clinicians is: What is
the upper age limit to offer oocyte cryopreservation? Be-
cause one cannot place an absolute value on childbearing,
the upper age limit for considering oocyte cryopreservation
may vary according to individual preferences, values, and
finances. Given the data presented in the current study, it
is reasonable to counsel women aged more 40 that, if she
forms embryos by minimal stimulation IVF, each embryo
transferred has a very low chance (only 5.3 %) of yielding a
live birth. In conclusion, this report extends the body of lit-
erature reported on oocyte cryopreservation in younger
women and in women who undergo conventional IVF to
those undergoing minimal stimulation IVF.
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